Avid Bioservices Inc (CDMO)

[hutschi]

Hyperprogression on Checkpoint Inhibition Immunotherapy

However, most patients who receive treatment with checkpoint inhibitors, do not experience spectacular responses. What is more troubling is that some patients actually progress rapidly once checkpoint inhibition therapy is initiated. These patients are called “hyperprogressors,” and it is essential to identify hyperprogressors before initiating treatment.

https://blogs.shu.edu/cancer/2017/03/22/hyperprogression-on-checkpoint-inhibition-immunotherapy/#more-4337